To include your compound in the COVID-19 Resource Center, submit it here.

FDA lifts hold for fulranumab in cancer pain

Johnson & Johnson (NYSE:JNJ) said FDA lifted a clinical hold on a Phase II

Read the full 141 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE